Abstract:Evidence has emerged that some healthy individuals with a history of exposure to Mycobacterium tuberculosis (Mtb) can develop protective antibody responses. However, it is not known whether patients with active tuberculosis elicit protective antibodies, and if they do, which bacterial antigens are targeted. To investigate the B cell responses during active infection, we generated a panel of monoclonal antibodies isolated from memory B cells of one patient. The antibodies, members of four distinct B cell clones, were directed against the Mtb phosphate transporter subunit PstS1. Antibodies p4–36 and p4–163 from two different B cell clones showed protective efficacy against Mtb and Mycobacterium bovis- BCG in an ex vivo human whole blood growth inhibition assay. Germline versions of p4–36 and p4–163 could no longer bind Mtb, implying that affinity maturation was vital for their activity. Crystal structures of p4–36 and a closely related clonal variant of p4–163, p4–170, complexed to PstS1 were determined at a resolution of 2.1Å and 2.4Å and revealed that the two antibodies recognize two distinctive epitopes on PstS1. As a proof of principle, p4–36 and p4–163 were used in a passive vaccination setting in aerosol Mtb-infected Balb/c mice, where both antibodies reduced bacterial lung burden by 50% after a single injection prior to Mtb infection. Our study shows that inhibitory B cell responses arise during active tuberculosis and identifies PstS1 as a target for elicitation of anti-Mtb antibodies. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial For human Tuberculosis patients: protocols number 33.18. and 0058, for healthy human donors: 2014-2-25 ### Funding Statement This study was funded by Israeli Science Foundation grant 1422/18 to N. T. Freund and Israeli Innovation Authority grant 65029 to N. T. Freund, as well as a National Natural Science Foundation of China grant (81661128044) to B. Javid, who is a Welcome Trust Investigator ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes all data associated with a paper is available, and can be accessed

Correction: Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis

Real-world diagnostic accuracy of lipoarabinomannan in three non-sputum biospecimens for pulmonary tuberculosis disease

Performance of urine lipoarabinomannan assays for paediatric tuberculosis in Tanzania

A Novel Quantitative Urine LAM Antigen Strip for Point-of-care Tuberculosis Diagnosis in Non-Hiv Adults.

Generation of mycobacterial lipoarabinomannan-specific monoclonal antibodies and their ability to identify mycobacterium isolates

Lipoarabinomannan in sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: Analytic validation and evaluation in two cohorts

Novel Monoclonal Antibodies To Esat-6 And Cfp-10 Antigens For Elisa-Based Diagnosis Of Pleural Tuberculosis

Novel automated AIMLAM for diagnosis of Mycobacterium tuberculosis

Point-Of-Care Urine LAM Tests for Tuberculosis Diagnosis: A Status Update

Development and preliminary evaluation toward a new tuberculosis treatment monitoring tool: the PATHFAST TB LAM Ag assay

Combination of exhaled breath condensate samples with lipoarabinomannan point of care assay for pulmonary tuberculosis (TB) diagnosis: protocol for a diagnostic accuracy study

Improving the diagnosis of active tuberculosis: a novel approach using magnetic particle-based chemiluminescence LAM assay

Utility of Urine Lipoarabinomannan (LAM) in Diagnosing Mycobacteria Infection among Hospitalized HIV-positive Patients

Diagnostic value of Lipoarabinomannan antigen for detecting Mycobacterium tuberculosis in adults and children with or without HIV infection

Exploring the eligibility of all reported lipoarabinomannan-testing assays in different clinical situations: a systematic review and meta-analysis of 97 articles

Performance of a Novel Algorithm Using Automated Digital Microscopy for Diagnosing Tuberculosis

Proteinase K-pretreated ConA-based ELISA assay: a novel urine LAM detection strategy for TB diagnosis

Sputum lipoarabinomannan (LAM) as a biomarker to determine sputum mycobacterial load: exploratory and model-based analyses of integrated data from four cohorts

Cytokine and Antibody Based Diagnostic Algorithms for Sputum Culture-Positive Pulmonary Tuberculosis

Human Antibodies Targeting a Transporter Mediate Protection Against Tuberculosis

Diagnostic accuracy of Lipoarabinomannan detection by lateral flow assay in pleural tuberculosis